A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 174 participants.

Also called NCT02111096

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose basic science
Phase
Phase 2
Enrolled
  • 174 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02111096
  • EudraCT 2013-004275-12
Other papers using this trial's data
  • Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes Diabetes, obesity & metabolism, 2017-08 DOI, PubMed 28191913

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Greece, Puerto Rico, Taiwan (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02111096. Randomized; triple masking; primary purpose basic science. Start 2014-04 (registry gives no type); primary completion 2015-09 (actual). Results posted on 2018-04-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
LY2409021
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Placebo
Intervention (Drug)
Metformin
Intervention (Drug)
Sulfonylurea
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct02111096
Content hash
9a87965fad5f7b36b6aaafabc89f25665e6a47dc9f37208c693c9852490c43f7